Gainers
- Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading.
- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) rose 34.3% to $0.2850 in pre-market trading after gaining over 6% on Thursday.
- ECB Bancorp, Inc. (NASDAQ: ECBK) rose 34.1% to $18.90 in pre-market trading after jumping more than 40% on Thursday.
- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) rose 23.3% to $0.6455 in pre-market trading. The U.S. Food and Drug Administration (FDA) recently declined to issue an Emergency Use Authorization (EUA) for NRx Pharmaceuticals’ lead drug ZYESAMI (aviptadil) for subgroup of patients with critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir.
- Senti Biosciences, Inc. (NASDAQ: SNTI) rose 19.4% to $2.22 in pre-market trading after declining 5% on Thursday.
- CHW Acquisition Corporation (NASDAQ: CHWA) rose 16.8% to $10.80 in pre-market trading. CHW Acquisition’s stockholders approved proposed merger transaction with Wag Labs, Inc.
- Amazon.com, Inc. (NASDAQ: NASDAQ:AMZN) rose 12% to $136.90 in pre-market trading after the company reported better-than-expected results for its second quarter. The company said it expects-third quarter net sales to be in a range of $125 billion to $130 billion, up 13% to 17% year-over-year.
- MICT, Inc. (NASDAQ: MICT) rose 10.5% to $0.6749 in pre-market trading after declining 9% on Thursday.
- RCM Technologies, Inc. (NASDAQ: RCMT) rose 9.9% to $18.40 in pre-market trading after declining around 9% on Thursday.
- Reviva Pharmaceuticals Holdings, Inc.. (NASDAQ: RVPH) rose 8.9% to $0.9178 in pre-market trading.
- Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 8.7% to $2.75 in pre-market trading after dropping 5% on Thursday.
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) rose 6.3% to $2.55 in pre-market trading. Lexicon Pharmaceuticals shares dropped around 27% on Thursday after the company announced pricing of an $85 million public offering and concurrent private placement.
- CarLotz, Inc. (NASDAQ: LOTZ) shares rose 5.7% to $0.46 in pre-market trading. CarLotz is expected to release its Q2 results on August 8, 2022.
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) rose 5.4% to $0.42 in pre-market trading. Akebia Therapeutics is expected to release its Q2 financial results on Thursday, August 4, 2022.
- Apple Inc (NASDAQ:AAPL). (NASDAQ: APPL) rose 2.3% to $161.03 in pre-market trading as the company reported better-than-expected results for its fiscal year third-quarter, helped by strong iPhone and iPad sales.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers
- Roku, Inc. (NASDAQ: ROKU) shares fell 24.3% to $64.45 in pre-market trading after the company reported weaker-than-expected financial results for its second quarter and withdrew its full-year revenue growth guidance. Roku said it expects third-quarter revenue to increase about 3% year-over-year to $700 million.
- DexCom, Inc. (NASDAQ: DXCM) fell 15.5% to $73.40 in pre-market trading after the company reported worse-than-expected Q2 EPS and sales results.
- Avaya Holdings Corp. (NASDAQ: AVYA) fell 13.8% to $1.80 in pre-market trading after the company cut Q3 revenue guidance. Avaya also named Alan Masarek as CEO.
- VolitionRx Limited (NYSE: VNRX) fell 12.3% to $2.00 in pre-market trading after the company announced a proposed underwritten public offering of common stock.
- Missfresh Limited (NASDAQ: MF) shares fell 10.6% to $0.1210 in pre-market trading after the company adopted significant business strategy adjustments. The company received RMB200 million equity investment pursuant to investment agreement and highlighted temporary shutdown of on-demand distributed mini warehouse.
- Avantor, Inc. (NYSE: AVTR) shares fell 10.2% to $29.00 in pre-market trading after the company reported worse-than-expected Q2 EPS and sales results.
- Intel Corporation (NASDAQ: NASDAQ:INTC) fell 9.8% to $35.84 in pre-market trading after the company reported worse-than-expected Q2 EPS and sales results. The company also issued Q3 and FY22 EPS and sales guidance below analyst estimates.
- ObsEva SA (NASDAQ: OBSV) fell 7.3% to $0.2801 in pre-market trading as the company reported the resignation of Jean-Pierre Gotteland, Chief Scientific Officer and Head of Research & Development, effective September 30, 2022.
Read at Benzinga
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.